Lixte Stock Valuation

LIXT -  USA Stock  

USD 2.72  0.07  2.51%

What would the acquisition value of Lixte Biotech Hlds be today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Lixte Biotech, is its stock price multiplied by the total number of shares outstanding, calculating Lixte Biotech's enterprise value requires a different approach. It uses Lixte Biotech's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Lixte Biotech Hlds secures a last-minute Real Value of $2.39 per share. The latest price of the firm is $2.72. Based on Macroaxis valuation methodology, the firm appears to be overvalued. Our model forecasts the value of Lixte Biotech Hlds from analyzing the firm fundamentals such as Shares Owned by Insiders of 67.85 %, return on equity of (95.04) %, and Current Valuation of 35.93 M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.

Search Valuation 

 
Refresh
Lixte Biotech Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Lixte Biotech's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Overvalued
Today
2.72
29th of July 2021
Share
Please note that Lixte Biotech's price fluctuation is very risky at this time. Calculation of the real value of Lixte Biotech Hlds is based on 3 months time horizon. Increasing Lixte Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Lixte Biotech Hlds is useful when determining the fair value of the Lixte stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Lixte Biotech. Since Lixte Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lixte Stock. However, Lixte Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
2.39
Real Value
6.90
Upside
Estimating the potential upside or downside of Lixte Biotech Hlds helps investors to forecast how Lixte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lixte Biotech more accurately as focusing exclusively on Lixte Biotech's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.572.903.22
Details
Hype
Prediction
LowEstimated ValueHigh
0.142.767.27
Details
Naive
Forecast
LowNext ValueHigh
0.052.647.15
Details

Lixte Biotech Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Lixte Biotech's current stock value. Our valuation model uses many indicators to compare Lixte Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lixte Biotech competition to find correlations between indicators driving Lixte Biotech's intrinsic value. More Info.
Lixte Biotech Hlds is rated below average in beta category among related companies. It is currently regarded as number one stock in price to book category among related companies .

About Lixte Biotech Valuation

The equity valuation mechanism determines the current worth of Lixte Biotech Hlds on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Lixte Biotech Hlds. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lixte Biotech Hlds based exclusively on its fundamental and basic technical indicators. By analyzing Lixte Biotech's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Lixte Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lixte Biotech. We calculate exposure to Lixte Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Lixte Biotech's related companies.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Lixte Biotech Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Lixte Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio31.93
Additionally, see Stocks Correlation. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.